PRT-1419 is under clinical development by Prelude Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRT-1419’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRT-1419 is under development for the treatment of solid tumors, sarcoma, melanoma, small cell lung cancer, non-small cell lung cancer, DLBCL, triple negative breast cancer, relapsed and refractory hematologic malignancies including multiple myeloma (MM), t-cell lymphomas, chronic myelomonocytic leukemia (CMML), non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia, B-cell non-hodgkin lymphoma (NHL) including follicular lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma, myeloproliferative neoplasm overlap syndrome and high-risk myelodysplastic syndrome (MDS). The drug candidate is administered by oral route and intravenous route of administration. It acts by targeting MCL1.
Prelude Therapeutics overview
Prelude Therapeutics (Prelude) is a biopharmaceutical company focused on discovering as well as developing small molecule therapies for the treatment of cancers with high unmet need. The company leverages its core competencies in medicinal chemistry and cancer biology coupled with agnostic approach target class and technology platform for drug discovery and creating new chemical entities. Pipeline candidates of the company include PRT543 for solid tumors and myeloid malignancies; PRT811 for GBM and CNS metastatic cancers; PRT1419 and PRT2527 for hematological malignancies; PRT-SCA2 for multiple genomically cancer and PRT-K4 for solid tumors. Prelude is headquartered in Wilmington, Delaware, the United States.
For a complete picture of PRT-1419’s drug-specific PTSR and LoA scores, buy the report here.